The preparation of leukemia cell vaccine expressing BCG heat shock protein 70 and anti-leukemia effect in vitro

Li, Xiaoling; Sun, Lijun; Wang, Zhi; Sun, Xin

doi:10.1016/j.intimp.2012.07.022

Cited by 4 publications

(3 citation statements)

References 29 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, the immunogenicity of AML and ALL cells was enhanced by transfection with the HSP70 gene of BCG (Bacille Calmette–Guérin). Short-term culture of those leukemia cells exhibited an increased number, no change in antigen expression, and enhanced immunogenicity with beneficial anti-leukemia effects [ 90 ]. Strategies indirectly targeting HSP70 have also been explored.…”

Section: Hsp70 and Its Targeting In Onco-hematological Diseasesmentioning

confidence: 99%

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?

et al. 2023

View full text Add to dashboard Cite

The search for molecules to be targeted that are involved in apoptosis resistance/increased survival and pathogenesis of onco-hematological malignancies is ongoing since these diseases are still not completely understood. Over the years, a good candidate has been identified in the Heat Shock Protein of 70kDa (HSP70), a molecule defined as “the most cytoprotective protein ever been described”. HSP70 is induced in response to a wide variety of physiological and environmental insults, allowing cells to survive lethal conditions. This molecular chaperone has been detected and studied in almost all the onco-hematological diseases and is also correlated to poor prognosis and resistance to therapy. In this review, we give an overview of the discoveries that have led us to consider HSP70 as a therapeutic target for mono- or combination-therapies in acute and chronic leukemias, multiple myeloma and different types of lymphomas. In this excursus, we will also consider HSP70 partners, such as its transcription factor HSF1 or its co-chaperones whose druggability could indirectly affect HSP70. Finally, we will try to answer the question asked in the title of this review considering that, despite the effort made by research in this field, HSP70 inhibitors never reached the clinic.

show abstract

Section: Hsp70 and Its Targeting In Onco-hematological Diseasesmentioning

confidence: 99%

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…HSP70 and other HSP family members endogenously bind antigenic peptides in tumor or virus-infected cells. Such HSP70-peptide complexes, formed by fusing antigens to HSP70, are capable of inducing potent antitumor [33], [34], [35], [36] or antiviral immunity [25], [37], [38]. Genetically fusing antigens to HSP70 leads to an enhanced vaccine potency.…”

Section: Introductionmentioning

confidence: 99%

Induction of Specific Humoral and Cellular Immune Responses in a Mouse Model following Gene Fusion of HSP70C and Hantaan Virus Gn and S0.7 in an Adenoviral Vector

Cheng

Lan

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Heat shock proteins (HSPs) display adjuvant functions when given as fusion proteins to enhance vaccination efficiency. To evaluate enhanced potency of Hantaan virus (HTNV) glycoprotein (GP) and nucleocapsid protein (NP) immunogenicity by heat shock protein 70 (HSP70), a recombinant adenovirus rAd-GnS0.7-pCAG-HSP70C expression vector was developed by genetically linking the HSP70 C-terminal gene (HSP70 359–610 aa, HSP70C) to the Gn and 0.7 kb fragment of the NP (aa1–274-S0.7). C57BL/6 mice were immunized with these recombinant adenoviral vectors. A series of immunological assays determined the immunogenicity of the recombinant adenoviral vectors. The results showed that rAd-GnS0.7-pCAG-HSP70C induced a stronger humoral and cellular immune response than other recombinant adenoviruses (rAd-GnS0.7-pCAG and rAd-GnS0.7) and the HFRS vaccine control. Animal protection experiments showed that rAd-GnS0.7-pCAG-HSP70C was effective at protecting C57BL/6 mice from HTNV infection. The results of the immunological experiments showed that HSP70C lead to enhanced vaccine potency, and suggested significant potential in the development of genetically engineered vaccines against HTNV.

show abstract

“…At present time we're seeing a renewed interest around the world towards experimental and clinical immunotherapy [22][23][24][25][26][27][28] and identification of LAA [26,29]. In particular, RHAMM/receptor for the hyaluronan acid had been listed among possible candidates for LAA in AML [30,31] and used for immunotherapy [31,32].…”

mentioning

confidence: 99%

Disease-Free Remission Exceeding 37 Years in Patients Treated as Children for Acute Leukemia (AL) with Immunotherapy Using Viable (Cryopreserved) Allogeneic Leukemic Cells Pages 254-26

Bulycheva

2013

J. Can. Res. Updates

View full text Add to dashboard Cite

At present time in spite of great achievements in modern chemotherapy of acute leukemia (AL) the issue of eradication of residual leukemic cells (MRD) is still relevant. Since 1971 we included specific immunotherapy in the treatment of children with acute lymphoblastic leukemia in remission using viable cryopreserved allogeneic leukemic cells. 67 children in remission were divided into 2 groups: 27 constituted the control group (only continued standard-forthat-time chemotherapy) and 40 children-the treatment which received immunotherapy in addition to standard chemotherapy. In 3 years all children in the control group relapsed. The median length of remission was 15 months. In the treatment group we observed stabilization of remission only in children over 7 years of age when immunization was initiated after 6 or more months of remission and in children younger than 7 if it was initiated after 1-1,5 years of remission. The median length of remission was 60 months which significantly exceeded (4 times) that parameter in the control group of children. Cytotoxic antibodies against leukemic cells appeared in the serum of effectively immunized children at a higher titer than against donor lymphocytes. Intrathecal administration of this hyperimmune serum to patients with neuroleukemia resistant to chemotherapy led to a sharp decrease in the amount of leukemic cells in the spinal fluid. After 5 years of remission (and 3-5 years of immunotherapy) all treatment in these patients was stopped. Out of 19 patients who received immunotherapy on time, 8 patients (42%) have been in event-free remission for 37 to 41 years (median-38 years) through the present time and enjoy high quality of life. Our results indicate that immunotherapy initiated during remission period of AL can lead to creation of anti-leukemic immunity with subsequent eradication of MRD and complete recovery.

show abstract

The preparation of leukemia cell vaccine expressing BCG heat shock protein 70 and anti-leukemia effect in vitro

Cited by 4 publications

References 29 publications

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?

Induction of Specific Humoral and Cellular Immune Responses in a Mouse Model following Gene Fusion of HSP70C and Hantaan Virus Gn and S0.7 in an Adenoviral Vector

Disease-Free Remission Exceeding 37 Years in Patients Treated as Children for Acute Leukemia (AL) with Immunotherapy Using Viable (Cryopreserved) Allogeneic Leukemic Cells Pages 254-26

Contact Info

Product

Resources

About